Gene Therapy Sector Faces FDA Turmoil and Leadership Changes
Originally Published 6 months ago — by Barron's
The departure of FDA official Nicole Verdun, who oversaw gene and cell therapies, has caused concern among biotech investors amid ongoing regulatory turbulence, ideological disagreements within the FDA, and recent safety issues affecting gene therapy companies, leading to declines in biotech stocks.
